Much of our present understanding of oncogenic HH/GLI signaling stems from the genetic and molecular analysis of basal cell carcinoma (BCC), a very frequent nonmelanoma skin cancer, and medulloblastoma (MB) development [59,60]. This evidence concerns the gene GLI1 and skin basal cell carcinoma.